Edition:
India

Shionogi & Co Ltd (4507.T)

4507.T on Tokyo Stock Exchange

6,209JPY
16 Jan 2018
Change (% chg)

¥37 (+0.60%)
Prev Close
¥6,172
Open
¥6,179
Day's High
¥6,215
Day's Low
¥6,163
Volume
785,300
Avg. Vol
1,297,870
52-wk High
¥6,465
52-wk Low
¥5,337

Chart for

About

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company, mainly engaged in the research, development, purchase, manufacture and sale of pharmaceuticals, as well as pharmaceutical-related businesses. The Company mainly provides its products and services in Japan, Europe and North America markets.

Overall

Beta: 0.99
Market Cap(Mil.): ¥2,061,380.00
Shares Outstanding(Mil.): 329.14
Dividend: 38.00
Yield (%): 1.15

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-R&I affirms Shionogi & Co Ltd's rating at "A+" and says stable outlook-R&I

* Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I

15 Dec 2017

BRIEF-Shionogi to repurchase shares and retire treasury shares

* Says it will repurchase up to 4.8 million shares, representing 1.5 percent of outstanding

27 Nov 2017

U.S. FDA approves first two-drug HIV regimen in win for GSK

The U.S. Food and Drug Administration has approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at lessening the side effect burden of current treatments that combine three or four medicines.

22 Nov 2017

UPDATE 2-U.S. FDA approves first two-drug HIV regimen in win for GSK

* Two-drug approach differentiates GSK from Gilead (Adds context on GSK drive to improve pharma sales)

22 Nov 2017

U.S. FDA approves first two-drug HIV regimen

NEW YORK, Nov 21 The U.S. Food and Drug Administration on Tuesday approved the first two-drug regimen to treat HIV, the virus that causes AIDS, aimed at easing the side effects for long-term patients who are on the standard treatment involving three or more drugs.

22 Nov 2017

BRIEF-UMN Pharma says business and capital alliance with Shionogi

* Says it signed business and capital alliance agreement with Shionogi & Co Ltd on Oct. 31

31 Oct 2017

BRIEF-Shionogi and Purdue Pharma announce U.S availability of Symproic (naldemedine)

* Shionogi inc - co, Purdue Pharma L.P. announce that Symproic (naldemedine) 0.2 mg tablets are now available throughout United States​

12 Oct 2017

BRIEF-Shionogi says Lusutrombopag met primary, secondary endpoints in phase 3 study​‍​

* Shionogi & Co Ltd - ‍ Lusutrombopag met primary and all pre-specified important secondary endpoints in a global phase 3 study​

25 Sep 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

20 Sep 2017

Shire, Shionogi's ADHD drug for adults clears late-stage trial in Japan

TOKYO, Sept 20 Shire Plc and Shionogi & Co Ltd said a drug to treat ADHD in adults had met its main goal in a late-stage trial in Japan, bringing it one step closer to approval in the world's third-biggest market for ADHD treatments.

20 Sep 2017

Earnings vs. Estimates